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The effect of an eicosapentaenoic acid-rich encapsulated 
preparation of fish oil on the incidence of early restenosis 
after coronary angioplasty was assessed by a randomized 
double-blind placebo-controlled study. A total of 108 pa- 
tients received either 10 capsules of fish oil (1.8 g eicosa- 
pentaenoic acid, 1.2 g docosahexaenoic acid) or 10 control 
capsules (50% olive oil, 50% corn oil), commencing the day 
before angioplasty and continuing for 4 months after angio- 
plasty, in addition to treatment with aspirin and verapamil. 
In 101(94%) of the 108 patients, follow-up angiographic 
or postmortem result was evaluated at a mean (*SD) of 100 
(222) days. Angiographic restenosis was observed in 34% 
of patients (29% of lesions) in the fish oil-treated group and 
33% of patients (31% of lesions) in the control group (no 
significant difference). The overall incidence of angio- 
There has been interest in diets rich in fish oils since a 
low incidence of coronary heart disease was reported in 
Greenland Eskimos in 1979 (1). The major prostanoid 
precursors in the diet of Eskimos are eicosapentaenoic 
acid (205 Omega-3) and docosahexaenoic acid (22:6 
Omega-3). In contrast, in the typical Western diet the 
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graphic restenosis was significantly higher in patients with 
1) recurrent angina pectoris, 2) a positive exercise test at 
follow-up after angioplasty, 3) residual stenosis >30% 
immediately after angioplasty, and 4) dilation of the left 
anterior descending or right coronary artery. 
Biochemical investigations showed a greater decrease in 
the serum triglyceride levels in the fish oil-treated group 
versus the control group (p < 0.05) but no differences 
between the two groups in cholesterol levels or platelet 
counts over the 4 month period. 
In conclusion, in this study, the administration of fish oil 
at a dose of 10 capsules/day did not reduce the incidence of 
early restenosis after coronary angioplasty. 
(J Am Coil Cardiol1989;13:665-72) 
predominant prostanoid precursor is linoleic acid (18:2 
Omega-6) (2). Eicosapentaenoic acid and docosahexaenoic 
acid have been reported to have a hypolipidemic effect 
(3,4). decrease platelet aggregation (5) and blood viscosity 
(6), increase red cell deformability (7) and alter the function 
of monocytes (8). However, no direct benefit from sup- 
plementation of the Western diet with eicosapentaenoic 
acid on complications of atherosclerosis has been demon- 
strated. 
Percutaneous transluminal coronary angioplasty has an 
accepted role in the management of coronary artery disease 
in human patients. This role is limited, in part, by the high 
incidence (30% to 40%) of early restenosis (9-12). This study 
was, therefore, undertaken to determine the effect of dietary 
supplementation with an encapsulated preparation of fish oil 
rich in eicosapentaenoic acid and docosahexaenoic acid on 
the incidence of early angiographic restenosis after coronary 
angioplasty. 
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Methods 
Study patients. The study was randomized and double- 
blind, and active treatment was compared with a vegetable 
oil control treatment. Consecutive patients who underwent 
angioplasty of a native coronary artery between October 
1984 and June 1986 were eligible for the study unless 1) the 
vessel dilated at angioplasty was not a native coronary artery 
(that is, saphenous vein graft), 2) the patient had undergone 
previous angioplasty, or 3) the vessel was totally occluded 
before angioplasty. In addition, if angioplasty was unsuc- 
cessful, patients were withdrawn from the study and not 
included in the follow-up results. 
Randomization. Informed consent was obtained from 128 
of 135 eligible patients on the day before coronary angio- 
plasty. These 128 patients were randomly assigned by the 
hospital pharmacy department to a treatment or a placebo 
group through use of a computer-generated list of random 
numbers. Doctors and patients were unaware of the group to 
which the patients were assigned. 
Medication, five 1 g fish oil capsules twice daily, was 
supplied by Seven Seas Health Care Limited, Hull, England 
and begun on the day before angioplasty. The capsules 
(Maxepa) contained a minimum of 18% eicosapentaenoic 
acid and 12% docosahexaenoic acid, a trace of cholesterol 
(0.6% w/w) and were stabilized with vitamin A and E (100 1 
CJg and 1 $g, respectively). Thus, a patient receiving 10 
capsules/day would ingest 1.8 g of eicosapentaenoic acid, 1.2 
g of docosahexaenoic acid and 60 mg of cholesterol. Patients 
in the control group received capsules containing 50% olive 
oil, 50% corn oil and no cholesterol. 
Angioplasty was successful (for definition, see the subse- 
quent discussion) in 108 (84%) of the 128 patients. Fifty-two 
of these 108 patients (with a total of 62 successfully dilated 
lesions) were randomized to receive fish oil, and 56 patients 
(with a total of 63 successfully dilated lesions) were random- 
ized to receive control capsules. 
Angioplasty procedure. On the day before angioplasty, 
patients began taking the study capsules, aspirin (150 mg/ 
day) and verapamil (80 mg three times a day) and they 
stopped receiving beta-adrenergic blocking agents. During 
angioplasty, nifedipine (20 mg sublingually) and heparin 
(10,000 U bolus intraarterially) were given, and intravenous 
infusions of dextran-40 in glucose (1,000 ml, 100 ml/h) and 
nitroglycerin (8 to 25 pg/min) were begun. 
Postprocedure medication. Nitroglycerin and heparin in- 
fusions (1,000 U/h) were continued for 24 h after angioplasty. 
Aspirin, verapamil and the study capsules were continued 
until repeat angiography was performed. 
Laboratory procedures. Blood samples for fasting choles- 
terol levels, triglyceride levels, platelet counts and plasma 
lipid fatty acid analysis were taken on the morning of 
angioplasty and on the morning of the follow-up angiogram. 
Plasma lipid fatty acid analysis (arachidonic acid concentra- 
tion, eicosapentaenoic acid concentration and the ratio of 
plasma arachidonic acid to eicosapentaenoic acid) was per- 
formed in a random sample of 33 patients taking fish oil 
capsules and 12 patients taking the control capsules. Analy- 
sis was measured by capillary gas liquid chromatography 
(13). 
Assessment of compliance. All patients were questioned 
about capsule intake at the time of follow-up angiography. In 
addition, compliance was assessed by subsequent analysis of 
the plasma lipid fatty acid composition. 
Follow-up. All patients were assessed for recurrence of 
chest pain at the time of follow-up angiography. A treadmill 
exercise test was performed according to the Bruce protocol 
(14) in 82 (82%) of the 100 patients on the day before the 
follow-up angiogram. The exercise test was considered 
positive if there was horizontal or downsloping depression of 
the ST segment of 20.1 mV for at least 0.08 s after the J 
point in three consecutive complexes. 
Coronary angiography was performed in all patients at 
the time of angioplasty and repeated in 100 (93%) of the 108 
patients at a mean (tSD) of 100 (+2) days (range 70 to 190) 
after angioplasty. In the one patient who died, the coronary 
vessels were examined at autopsy. The degree of stenosis 
was expressed as percent diameter reduction. Measure- 
ments were taken with a caliper at the smallest luminal 
diameter, compared with the closest normal segment and 
averaged in at least two orthogonal views by two indepen- 
dent investigators who were unaware of the patients’ treat- 
ment group. When the investigators disagreed on the pres- 
ence of restenosis (as occurred on 13 of 117 occasions), a 
consensus reading was obtained. Transstenotic pressure 
gradient was defined as the pressure gradient between the 
mean pressures recorded from the tips of the dilation and 
guiding catheters while the deflated balloon was across the 
lesion. 
Successful angioplasty was dejined as an increase in the 
degree of coronary artery diameter of 220% and absence of 
myocardial infarction, death or coronary artery bypass graft 
surgery during the initial hospitalization (15). Restenosis was 
defined as loss of >50% of the gain in luminal diameter at 
angioplasty (11). Patients with recurrent stenosis in only one 
of two dilated lesions were classified as having restenosis. 
Statistical analysis. Standard t test and contingency table 
analyses were performed for univariate comparisons of 
differences. For variables such as age, serum cholesterol, 
severity of coronary stenosis and transstenotic gradient, 
testing was performed by both contingency table and linear 
regression analysis. Multivariate analyses were carried out 
by linear modeling, assuming normal errors, using the stan- 
dard statistical package GLIM (16). Unless otherwise spec- 
ified, results are termed not significant if the nominal p value 
was >0.05. 
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Table 1. Baseline Clinical Characteristics of 108 Patients Table 2. Baseline AngiograDhic Characteristics of 108 Patients 
Fish 
Oil-Treated 
Group 
(n = 52) 
Control 
Group 
(n = 56) 
P 
Value 
Fish 
Oil-Treated 
Group 
(n = 52) 
Control 
Group 
tn = 56) p Value 
Age (mean t SD) (yrl 
No. of men 
Severity of angina 
(CHA grade) 
I-II 
III 
IV 
Recent MI 
Duration of angina 
Mean + SD (mo) 
53 mo 
>3 mo 
Cholesterol* 
Mean 2 SE 
(mmoliliter) 
~6.5 mmoliliter 
Triglycerides* 
Mean ? SE 
(mmoliliter) 
22.0 mmoliliter 
Platelet count 
Mean + SE 
(X IO’iIiter) 
51.8 t 9.9 
40 (77%) 
x (15%) 
IO (19%) 
34 (66%) 
4 (8%) 
12.3 (21.7) 
30 (57%) 
22 (43%;) 
5.54 * 0.2 
6 of 43 (14%) 
1.82 f 1.17 
I5 of 43 (34%) 
294 + 9 
55.1 2 11.6 
49 (88%) 
6(ll%) 
9 (16%) 
41 (73%) 
2 (4%) 
13.5 (25.8) 
36 (65%) 
20 (35%) 
5.72 + 0.16 
9 of 49 (18%) 
1.65 + 0.83 
1 I of 49 (23%) 
290 5 9 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
*Results available in 43 of 52 fish oil-treated patients and 49 of 56 control 
patients within 6 weeks before angioplasty. CHA = Canadian Heart Associ- 
ation: MI = myocardial infarction: NS = not significant at the p = 0.05 level. 
No. of vessels 
dilated/patient 
I vessel 
2 vessels 
Vessels dilated 
LAD 
RCA 
LCX 
Lengrh of lesion 
210 mm 
Calcified lesion 
Inflation ~60 s 
Severity of stenosis 
before PTCA 
<:757r 
75 to 94% 
2595% 
After PTCA 
530% 
>307r 
Trdnsstenotic gradient* 
before PTCA 
<:50 mm Hg 
~50 mm Hg 
After PTCA 
515 mm Hg 
>I5 mm Hg 
Intimal dissection present 
42 (XI%) 
IO (19%) 
23 (37%) 
I6 (26%) 
23 (37%) 
8 (13%) 
5 (8%) 
28 (47%) 
8 (13%) 
32 (52%) 
22 (35%) 
49 (79%) 
I3 (21%) 
21 (45%) 
26 (55%) 
2s (54%) 
21 (46%;) 
20 (32%) 
49 (87%) 
7 (13%) 
39 (62%) 
9 (14%) 
15 (24%) 
IO (16%) 
19 (30%) 
31 (50%) 
II 118%;) 
24 (38%) 
28 (44%;;) 
40 (63%) 
23 (37%) 
26 (44%) 
33 (56%) 
31 (55%) 
25 (45%) 
16 (25%) 
NS 
co.05 
NS 
<O.Ol 
NS 
NS 
NS 
NS 
NS 
Results 
Comparison of baseline characteristics. The data on se- 
lected clinical and angiographic variables are shown in 
Tables 1 and 2. In summary, there were no significant 
differences in baseline patient characteristics between the 
two groups, either with or without adjustment for age and 
gender. The only noteworthy baseline angiographic differ- 
ences were a higher number of 1) dilations of the left anterior 
descending coronary artery, and 2) calcified lesions in the 
control group versus the active treatment group. 
Follow-up clinical results. No patient sustained an acute 
occlusion after leaving the catheterization laboratory or 
underwent coronary surgery during the follow-up period. 
One patient in the fish oil-treated group died suddenly 3 
months after angioplasty and another patient in this group 
sustained a nonfatal myocardial infarction 4 weeks after 
angioplasty. All patients had angina pectoris before angio- 
plasty, and at follow-up study 35 (32%) of the 108 patients 
had recurrence of chest pain, including 7 patients with grade 
IV angina pectoris. Twenty (24%) of the 82 patients who 
underwent symptom-limited treadmill exercise testing at the 
time of follow-up angiography had a positive result, includ- 
ing 3 of 5 patients who presented with grade IV angina. The 
*Results where available. LAD = left anterior descending coronary 
artery: LCx = left circumflex artery; NS = not significant at the p = 0.05 
level: PICA = percutaneous transluminal coronary angioplasty; RCA = right 
coronary artery. 
seven patients who did not have repeat angiography (five in 
the active treatment group and two in the control group) 
included the one patient who died and six patients who 
remained asymptomatic and refused the follow-up angio- 
gram. No patient was lost to follow-up. 
Follow-up angiograpbic results. The time interval be- 
tween angioplasty and repeat angiography was similar for 
both groups (98 2 22 days in the active treatment group and 
100 t 22 days in the control group). There was also no 
significant difference between the two study groups with 
respect to percent diameter stenosis before or immediately 
after angioplasty or at repeat angiography (Fig. 1). In the one 
patient who died in the active treatment group, examination 
of the coronary vessels at autopsy showed restenosis but not 
total occlusion of the dilated artery. 
Restenosis rate (Table 3). Angiographic restenosis was 
observed in 34 (34%) of the 101 patients and in 35 lesions 
(31%). There was no difference in restenosis rates between 
the fish oil-treated and control groups; restenosis occurred in 
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Figure 1. Degree of coronary artery stenosis before, immediately 
after and 3 to 4 months after coronary angioplasty in the fish 
oil-treated group (A) (n = 52) and the control group (P) (n = 56). 
There was no significant difference in the rate of restenosis between 
the two study groups. Circles = no restenosis; triangles = resten- 
osis. 
34% of patients (29% of lesions) in the active treatment 
group compared with 33% of patients (31% of lesions) in the 
control group. Three of the 101 patients (3%) (1 in the active 
group and 2 in the control group) showed total occlusion of 
the dilated artery on the follow-up angiogram, including the 
1 patient who sustained a myocardial infarction. 
Clinical and angiographic risk factors for restenosis (Table 
3). Patients in both the treatment and placebo groups 
showed a lower restenosis rate for 1) dilation of the circum- 
flex artery versus dilation of the left anterior descending or 
right coronary artery (p < 0.05), and 2) lesions in which 
immediate postangioplasty stenosis was 130% (p < 0.05). 
Both groups also showed a trend toward a lower restenosis 
rate in patients with less severe stenosis before angioplasty 
(p < 0.06). However, there was no difference in the reste- 
nosis rate between the fish oil-treated and control groups 
overall or in any of the variables outlined in Table 3. 
Correlation of clinical and angiographic follow-up results. 
Angiographic restenosis was observed in 18 (51%) of the 35 
patients with recurrent symptoms compared with 16 (24%) of 
66 patients who were asymptomatic (p < 0.01) (Fig. 2). 
Among the 34 patients with restenosis, 16 (47%) were 
asymptomatic. Eleven (55%) of the 20 patients with a 
positive exercise test at follow-up study showed angio- 
graphic restenosis compared with 14 (23%) of 62 patients 
with a negative exercise test (p < 0.01). Of patients who had 
both recurrence of chest pain and a positive exercise test at 
the time of follow-up angiography, 70% showed restenosis 
on the angiogram compared with 16% of patients with no 
recurrence of chest pain and a negative exercise test (p < 
0.001). However, 7 (29%) of the 24 patients with restenosis 
had both no recurrence of chest pain and a negative exercise 
test. 
Tolerance, acceptability and safety. The fish oil capsules 
were found to be palatable and acceptable. Three patients 
(two in the active treatment group and one in the control 
group) stopped taking their tablets because of gastrointesti- 
nal intolerance. Bleeding times were not measured. How- 
ever, no patient suffered from bleeding complications during 
follow-up. Biochemical investigations showed no change in 
platelet levels in either the active treatment or the control 
group over the follow-up period. 
Plasma lipid data (Table 4). There was no significant 
difference in triglyceride levels between the two groups 
either before or 4 months after angioplasty. However, the 
change in triglyceride levels in the treated group over the 4 
month period was significantly different from that in the 
placebo group (p < 0.02). Both groups showed a significant 
increase in cholesterol levels over the 4 month period, 
although there was no difference between the two groups. 
Plasma fatty acid results (Table 5). Supplementation of 
the diet with fish oil caused a significant lowering of the 
plasma arachidonic acid to eicosapentaenoic acid ratio over 
the follow-up period (due to a rise in plasma eicosapentae- 
noic acid levels) in all but two patients in the active treat- 
ment group (these two patients were known to have stopped 
taking the fish oil capsules and showed no change in this 
ratio). Patients taking control capsules showed no significant 
change in the plasma arachidonic acid to eicosapentaenoic 
acid ratio. 
Discussion 
This study shows that patients treated with dietary sup- 
plementation of fish oil in addition to aspirin and verapamil 
have a restenosis rate after coronary angioplasty similar to 
that in patients treated with aspirin and verapamil alone. 
Restenosis after angioplasty is known to occur almost ex- 
clusively within the first 4 months (12,17,18), with late 
restenosis being infrequent. Repeat angiography was ob- 
tained at 100 ‘- 22 days after angioplasty in 94% of patients. 
Thus, we presume that most patients with restenosis were 
detected in our study. 
Restenosis rates. Reported restenosis rates (9,12,17,19, 
20) vary greatly, partly because of the use of different 
definitions of restenosis and different rates of angiographic 
restudy. In this study (1 l), we defined restenosis according 
to the recommendations of the National Heart, Lung, and 
Blood Institute angioplasty registry (12) as loss of >50% of 
the gain in luminal diameter at angioplasty. Some investiga- 
tors (18) now favor a definition of restenosis as a lesion 
causing >50% luminal diameter narrowing, where initial 
angioplasty success is defined as an immediate postangio- 
plasty diameter stenosis of ~50%. With use of these latter 
definitions, the restenosis rate in our study was 31% of 
patients (30% of patients in the active treatment group and 
32% of patients in the control group) and, again, there was no 
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Table 3. Comparison of Restenosis Rates Between the Two Study Groups 
Rate of Restenosis: 
No. (c/c) 
Fish Oil-Treated Group Control Group p Value* (fish 
(patients n = 47: (patients n = 54: oil-treated versus 
Variable arteries n = 561 arteries n = 61) control group) 
Total patients 16 (341 18 (331 NS 
Age 
<60 yr 10 (29) 10 (28) NS 
~60 yr 6 (42) 8 (401 
Gender 
Male 11 (31) 14 (30) NS 
Female 5 (421 4 (57) 
Severity of angina (CHA grade) 
I-II 3 (43) 2 (29) NS 
III I(131 3 (30) 
IV 12 (38) 13 (38) 
Duration of angina 
23 mo 8 (30) I4 (40) NS 
>3 mo 8 (401 4 (211 
Cholesterol level (mmoliliter) 
c6.5 13 (36) 9 (23) NS 
z6.S I(l7) 3 (30) 
Total vessels 16 (29) I9 (31) 
Vessels dilated 
LAD 9 (43) I I (26) NS 
RCA 6 (321 7 (53) 
LCX I (8) I (Ill 
Calcification 
Present I (30) 6 (331 NS 
Absent 15 (31) I3 (311 
Inflation > 60 s 
Yes 9 (39) 12 (39) NS 
No 7 (27) 7 (24) 
Severity of stenosis 
Before PTCA 
<75% 0 (0) 2 (22) NS 
75 to 94% 7 129) 8 (33) 
295% 9 (45) 9 (36) 
After PTCA 
230% 12 (28) 9 (23) NS 
>30% 4 (44) IO (451 
Transstenotic gradient? 
Before PTCA 
~50 mm Hg 4 (19) 6 (23) NS 
250 mm Hg 8 (311 II (33) 
After PTCA 
515 mm Hg 5 (20) 10 (32) NS 
>I5 mm Hg 7 (33) 7 (28) 
Intimal dissection 
Present 6 (30) 5 (29) NS 
Absent IO (29) 14 (30) 
*Results available in 43 of 47 patients in fish oil-treated group and 49 of 54 control patients. tTransstenotic gradients were obtained in 106 of 117 vessels before 
angioplasty and 103 of I17 vessels after angioplasty. Abbreviations as in Table 2. 
difference in restenosis rates between fish oil-treated and 
control groups overall or in any of the variables outlined in 
Table 3. Kaltenbach et al. (171, who also obtained follow-up 
angiography in 94% of patients, reported a significantly 
lower angiographic restenosis rate: 17% among 356 patients. 
Apart from their use of high dose aspirin in their patients (1.5 
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Figure 2. Probability of restenosis in patients with (n = 
35) and without (n = 66) recurrent symptoms and a 
positive exercise test at 3 to 4 months after coronary 
angioplasty. *Both angina and exercise test. 
1 
AffiINA EXERCISE TEST 0OTl-H 
FOUR MONTHS POST ANGIOPLASTY 
g/day), there was no difference in medical treatment, tech- restenosis. A third-the degree of stenosis before angio- 
nique of angioplasty or patient selection, and the explanation plasty-would probably also have been predictive had the 
of their superior results remains unclear. sample size been larger. 
Restenosis was present in 51% of our patients with 
recurrent symptoms and in 55% of patients with a positive 
exercise stress test. However, 38% of patients with reste- 
nosis were asymptomatic. As in two previous studies 
(10,12), our study suggests that clinical status and results of 
exercise stress tests are not reliable means to detect the 
presence of restenosis. 
Effects of fish oil. We observed a modest but significant 
lowering of the triglyceride levels in patients treated with fish 
oil compared with control patients. This effect of eicosapen- 
taenoic acid on circulating triglyceride levels is well known, 
with the lowering effect reported to be directly proportional 
to the dose of fish oil and to the pretreatment triglyceride 
levels (4,6,21). 
In our study, no clinical factors were identified as predic- 
tors of restenosis. Two angiographic variables-the artery 
undergoing dilation and the degree of immediate postangio- 
plasty stenosis-were identified as univariate predictors of 
The efects of eicosapentaenoic acid on total cholesterol 
and low density lipoprotein levels appear to be less pro- 
nounced and unpredictable (21,221, and in our ‘study there 
was no difference in cholesterol level between the active 
Table 4. Biochemical Results in the Two Study Groups 
Fish 
Oil-Treated 
Group* 
(n = 43) 
Control 
Group* 
(n = 49) p Value 
Platelet levels 
(mean f SE [X IO’lliter]) 
Before PTCA 
4 mo after PTCA 
Difference 
Triglyceride level 
(mean + SE [mmolkter]) 
Before PTCA 
4 mo after PTCA 
Difference 
Cholesterol level 
(mean + SE [mmollliter]) 
Before PTCA 
4 mo after PTCA 
Difference 
294 + 9 
280 2 9 
-1326 
1.82 rf: 1.17 
1.65 ? 1.19 
-0.22 * 0.15 
5.54 ? 0.20 
6.26 C 0.23 
+0.84 + 0.19 
(p < 0.001) 
290 k 9 
280 + 9 
-12 + IO 
1.65 k 0.83 
1.89 + 1.02 
to.29 It 0.14 
5.72 + 0.16 
6.15 + 0.19 
to.48 + 0.15 
(p < 0.002) 
NS 
NS 
NS 
NS 
NS 
co.02 
NS 
NS 
NS 
*Results not available in four patients in the fish oil-treated group and five patients in control group. 
Abbreviations as in Table 2. 
JACC Vol. 13, No. 3 GRIGG ET AL. 671 
March 1, 19X9:665-7? FISH OIL SUPPLEMENTATION AND RESTENOSIS 
Table 5. Summarv of Plasma Lipid Fatty Acid Results* 
Before 
Angioplasty 
At Follow-Up 
(I00 t 22 days 
after angioplasty) 
Fish oil-treated group In = 33) 
AA/EPA ratio 
AA (mgil00 ml) 
EPA (mg/lOO ml) 
Control group (n = 13) 
AA/EPA ratio 
AA (mgilO0 ml) 
EPA (mg/lOO ml) 
7.1 k 0.51 1.7 ? 0.24 
18.2 ? 1.42 17.2 + I.18 
3.1 + 0.43 14.4 2 1.47 
9.1 ? I.15 8.9 t 1.50 
15.6 2 1.44 17.6 i I.41 
I.8 2 0.14 2.6 + 0.35 
*Results expressed as mean t standard error. AA = arachidonic acid: 
EPA = eicosapentaenoic acid. 
treatment and control groups. Both groups, however, 
showed a highly significant rise in cholesterol level over the 
4 month follow-up period. This was attributed to a lowering 
of the preangioplasty cholesterol level because the blood 
sample was taken during a time of stress on the morning of 
coronary angioplasty. with 70% of patients presenting with 
grade IV angina pectoris. Effects of possible weight gain 
over the follow-up period were not excluded. 
The plasma aruchidonic to eicosapentaenoic acid ratio 
was an excellent measure qf compliance, with dietary sup- 
plementation of 10 capsules/day of fish oil causing a marked 
reduction in this ratio in all but two study patients who were 
known to have stopped taking the capsules. In view of the 
significant decrease in plasma arachidonic to eicosapentae- 
noic acid ratio and the significant rise in plasma eicosapen- 
taenoic acid levels, we believe the dose of fish oil used in this 
study was adequate (23). 
To oar knowledge, three other studies (24-26) have ex- 
amined the effect ofjsh oil on restenosis rates after coro- 
nary angioplasty. In contrast to our study, these studies 
reported beneficial effects in the groups treated with fish oil. 
Two studies (24.251, however, did not have angiographic 
follow-up. In the other study (26) an administration of the 
fish oil capsules began 1 week before angioplasty at a dose of 
3.2 g/day of eicosapentaenoic acid, whereas in our study the 
dose was 1.8 g/day of eicosapentaenoic acid, and adminis- 
tration began on the day before angioplasty. Because of the 
dramatic change in the plasma eicosapentaenoic acid level 
and the arachidonic to eicosapentaenoic acid ratio in our fish 
oil-treated group, we believe that the dose used in our study 
was adequate and that the higher dose used by the Dallas 
group (26) does not explain the different results. The dura- 
tion of fish oil treatment before coronary angioplasty may be 
important, particularly if its action is to reduce platelet 
aggregation, which quickly occurs at the site of dilation after 
successful coronary angioplasty (27). However, it is often 
difficult to start treatment I week before the procedure, 
especially. as in our study, when a large proportion of the 
patients undergoing angioplasty present with unstable angina 
pectoris. 
Effect of the combination of aspirin and eicosapentaenoic 
acid. In our study. all patients received 150 mg aspirin/day 
in addition to active or control capsules. This was because 
we and other investigators (28.29) believe that aspirin re- 
duces the risk of acute occlusion after angioplasty. No 
patient had undesirable bleeding effects, and the combina- 
tion appears quite safe. However, the effects of eicosapen- 
taenoic acid and aspirin in combination, compared with 
those of eicosapentaenoic acid alone, are not established 
(2223). It is possible that treatment of both groups with 
aspirin masked a beneficial effect on restenosis with eicosa- 
pentaenoic acid alone, particularly if the effect was mediated 
through an effect on platelet function. However, in view of 
the safety and simplicity of low dose aspirin treatment, an 
effect of eicosapentaenoic acid would be clinically relevant 
only if it was additive to or greater than that of aspirin. There 
was no evidence for this in our study. 
Power of the study. The risk of restenosis in the control 
group in our study was 33% (with 95% confidence limits 20% 
to 46%). We assumed that, for fish oil to be considered a 
truly effective adjunct to platelet inhibition therapy after 
angioplasty. the rate of restenosis should be reduced by half, 
that is, from 33% to 16.5%. With our sample size of 101 
patients. we had a 60% chance of detecting a 50% reduction 
in the restenosis rate with fish oil treatment, with an alpha 
error of 0.05 (one-sided test). To detect a reduction of a third 
or a quarter (that is, a decrease in the restenosis rate to 22% 
or 25%. respectively) with the power of the study at 80%. we 
would have needed a sample size of at least 400 and 740 
patients, respectively. Because we were not convinced that 
a reduction in the restenosis rate of this order would be 
clinically relevant, and to limit the period of enrollment to a 
maximum of 2 years, we stopped recruitment for our study 
after 108 patients were enrolled and accepted the limitations 
of the power of the study. These calculations are based on 
the measurement of restenosis as a binary outcome. 
Clinical implications and conclusions. Our study was car- 
ried out in a small number of patients and specifically 
excluded groups at a high risk of restenosis (prior restenosis. 
total occlusion). These preliminary results need to be con- 
firmed by large scale multicenter trials. However, the study 
provides evidence against the possibility that the combina- 
tion of fish oil and aspirin reduces the rate of early restenosis 
in patients undergoing angioplasty compared with the rate 
reduction achieved with aspirin therapy alone. 
The study provides accurate data on the rate of restenosis 
and evidence that 1) the degree of stenosis before and 
immediately after angioplasty is an important determinant of 
restenosis, emphasizing the importance of obtaining an 
initial optimal angiographic result: 2) the vessel dilated is an 
important predictor of restenosis, with angioplasty of the 
circumflex artery having a significantly lower restenosis rate 
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than that of the left anterior descending or right coronary 
artery; and 3) although the recurrence of angina pectoris and 
the results of an exercise test correlate with angiographic 
results, these data do not reliably predict the presence of 
restenosis. 
We are grateful to Seven Seas Health Care, Kingston-upon-Hull for supplying 
the Maxepa and placebo capsules, Grant Hopkins for technical assistance in 
the plasma lipid fatty acid analyses and Joyce Lygnos for secretarial assis- 
tance. 
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